|
1.
|
|
12 p, 801.4 KB |
The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
/
Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mestre, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jerez, Andrés (Vall d'Hebron Institut d'Oncologia) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. [...]
2023 -  10.3390/cancers15051483
Cancers, Vol. 15 Núm. 5 (march 2023) , p. 1483
|
|
|
2.
|
|
11 p, 4.1 MB |
The evolution of hematopoietic cells under cancer therapy
/
Pich, Oriol (Institut de Recerca Biomèdica) ;
Cortes-Bullich, A. (Institut d'Investigació Biomèdica Sant Pau) ;
Muiños, Ferran (Institut de Recerca Biomèdica) ;
Pratcorona, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Gonzalez-Perez, A. (Universitat Pompeu Fabra) ;
Lopez-Bigas, N. (Institució Catalana de Recerca i Estudis Avançats)
Chemotherapies may increase mutagenesis of healthy cells and change the selective pressures in tissues, thus influencing their evolution. However, their contributions to the mutation burden and clonal expansions of healthy somatic tissues are not clear. [...]
2021 - 10.1038/s41467-021-24858-3
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 4803
|
|
|
3.
|
|
|
4.
|
|
17 p, 5.1 MB |
Robust temporal map of human in vitro myelopoiesis using single-cell genomics
/
Alsinet, Clara (Open Targets. Wellcome Genome Campus) ;
Primo, Maria Nascimento (Open Targets. Wellcome Genome Campus) ;
Lorenzi, Valentina (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Bello, Erica (Open Targets. Wellcome Genome Campus) ;
Kelava, Iva (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Jones, Carla P. (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Vilarrasa Blasi, Roser (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Sancho Serra, Carmen (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Knights, Andrew J. (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Park, Jong Eun (Korea Advanced Institute of Science and Technology) ;
Wyspianska, Beata S. (Immunology Research Unit. Medicines Research Centre. GlaxoSmithKline) ;
Trynka, Gosia (Open Targets. Wellcome Genome Campus) ;
Tough, David F. (Immunology Research Unit. Medicines Research Centre. GlaxoSmithKline) ;
Bassett, Andrew (Open Targets. Wellcome Genome Campus) ;
Gaffney, Daniel J. (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Álvarez-Errico, Damiana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vento Tormo, Roser (Wellcome Sanger Institute. Wellcome Genome Campus)
Myeloid cells are central to homeostasis and immunity. Characterising in vitro myelopoiesis protocols is imperative for their use in research, immunotherapies, and understanding human myelopoiesis. Here, we generate a >470K cells molecular map of human induced pluripotent stem cells (iPSC) differentiation into macrophages. [...]
2022 - 10.1038/s41467-022-30557-4
Nature communications, Vol. 13 Núm. 1 (december 2022) , p. 2885
|
|
|
5.
|
|
9 p, 1.3 MB |
Towards a Better Understanding of Cohesin Mutations in AML
/
Cuartero, Sergi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Innes, A. J. (Faculty of Medicine. Centre for Haematology. Imperial College London) ;
Merkenschlager, M. (Imperial College London. Institute of Clinical Sciences) ;
Universitat Autònoma de Barcelona
Classical driver mutations in acute myeloid leukemia (AML) typically affect regulators of cell proliferation, differentiation, and survival. The selective advantage of increased proliferation, improved survival, and reduced differentiation on leukemia progression is immediately obvious. [...]
2019 - 10.3389/fonc.2019.00867
Frontiers in Oncology, Vol. 9 (september 2019) , p. 867
|
|
|
6.
|
|
15 p, 4.2 MB |
GATA2 Promotes Hematopoietic Development and Represses Cardiac Differentiation of Human Mesoderm
/
Castaño Cardoso, Julio (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Aranda, Sergi (Universitat Pompeu Fabra. Centre de Regulació Genòmica (CRG-UPF)) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Calero-Nieto, Fernando (Department of Hematology. Wellcome and MRC Cambridge Stem Cell Institute and Cambridge Institute for Medical Research. University of Cambridge) ;
Mejia-Ramirez, Eva (Centro de Medicina Regenerativa de Barcelona) ;
Mosquera, José Luis (Institut d'Investigació Biomèdica de Bellvitge) ;
Blanco, Enrique (Universitat Pompeu Fabra. Centre de Regulació Genòmica (CRG-UPF)) ;
Wang, Xiaonan (Wellcome and MRC Cambridge Stem Cell Institute and Cambridge Institute for Medical Research. University of Cambridge) ;
Prieto, Cristina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zabaleta, Lorea (Laboratory of Hematological Diseases. Fundación Inbiomed) ;
Mereu, Elisabetta (Centre de Regulació Genòmica) ;
Rovira, Meritxell (Centro de Medicina Regenerativa de Barcelona) ;
Jiménez-Delgado, Senda (Centro de Medicina Regenerativa de Barcelona) ;
Matson, Daniel Rusch (Department of Cell and Regenerative Biology. UW-Madison Blood Research Program. Carbone Cancer Center. University of Wisconsin School of Medicine and Public Health) ;
Heyn, Holger (Universitat Pompeu Fabra) ;
Bresnick, Emery H. (Department of Cell and Regenerative Biology. UW-Madison Blood Research Program. Carbone Cancer Center. University of Wisconsin School of Medicine and Public Health) ;
Göttgens, Berthold (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Di Croce, Luciano (Institució Catalana de Recerca i Estudis Avançats) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Raya, Ángel (Institució Catalana de Recerca i Estudis Avançats) ;
Giorgetti, Alessandra (Centro de Medicina Regenerativa de Barcelona) ;
Universitat Autònoma de Barcelona
In vertebrates, GATA2 is a master regulator of hematopoiesis and is expressed throughout embryo development and in adult life. Although the essential role of GATA2 in mouse hematopoiesis is well established, its involvement during early human hematopoietic development is not clear. [...]
2019 - 10.1016/j.stemcr.2019.07.009
Stem cell reports, Vol. 13 Núm. 3 (october 2019) , p. 515-529
|
|
|
7.
|
|
13 p, 3.9 MB |
Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions
/
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Calero-Nieto, Fernando (Department of Hematology. Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. University of Cambridge) ;
Wang, X. (Department of Hematology. Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. University of Cambridge) ;
Valdés-Mas, Rafael (Dreamgenics S.L. Oviedo) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ayllon, Veronica (Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica) ;
Real, P. J. (Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica) ;
Arambilet Mobilla, David (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Espinosa, Lluís (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Agraz-Doblás, Antonio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Varela, Ignacio (Universidad de Cantabria. Departamento de Biología Molecular) ;
De Boer, J. (University College London Great Ormond Street Institute of Child Health. Cancer Section) ;
Bigas Salvans, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gottgens, B. (Department of Hematology. Cambridge Institute for Medical Research and Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute. University of Cambridge) ;
Marschalek, Rolf (Institute of Pharmaceutical Biology. Goethe-University) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed in patients with t(4;11)+ B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is expressed in only half of the patients. [...]
2019 - 10.3324/haematol.2018.202044
Haematologica, Vol. 104 Núm. 6 (2019) , p. 1189-1201
|
|
|
8.
|
|
14 p, 3.9 MB |
Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome
/
Bereshchenko, O. (Department of Medicine. Department of Philosophy. Social Sciences and Education. University of Perugia) ;
Lo Re, O. (Department of Biology. Faculty of Medicine. Masaryk University) ;
Nikulenkov, F. (Department of Biology. Faculty of Medicine. Masaryk University) ;
Flamini, S. (Department of Medicine. Department of Philosophy. Social Sciences and Education. University of Perugia) ;
Kotaskova, J. (University Hospital Brno (República Txeca)) ;
Mazza, T. (IRCCS Casa Sollievo della Sofferenza. Bioinformatics Unit) ;
Le Pannérer, Marguerite Marie (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Giallongo, C. (Division of Hematology. A.O.U. Policlinico-OVE. University of Catania) ;
Palumbo, G. (Department of Medical and Surgical Sciences and Advanced Technologies GF Ingrassia. University of Catania) ;
Li Volti, G. (Department of Biomedical and Biotechnological Sciences. University of Catania) ;
Pazienza, V. (Gastroenterology Unit. IRCCS Casa Sollievo della Sofferenza) ;
Cervinek, L. (University Hospital Brno (República Txeca)) ;
Riccardi, C. (Department of Medicine. Department of Philosophy. Social Sciences and Education. University of Perugia) ;
Krejci, L. (Department of Biology. Faculty of Medicine. Masaryk University) ;
Pospisilova, S. (University Hospital Brno (República Txeca)) ;
Stewart, A. F. (Genomics. Biotechnology Center. Center for Molecular and Cellular Bioengineering. Technische Universität Dresden) ;
Vinciguerra, M. (International Clinical Research Center. St'Anne University Hospital) ;
Universitat Autònoma de Barcelona
Background: Epigenetic regulation is important in hematopoiesis, but the involvement of histone variants is poorly understood. Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic stem cell (HSC) disorders characterized by ineffective hematopoiesis. [...]
2019 - 10.1186/s13148-019-0724-z
Clinical Epigenetics, Vol. 11 Núm. 1 (22 2019) , p. 121
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
